tam6 Antibody

What is TMC6 and why are antibodies against it important in research?

TMC6, also known as EVER1 (Epidermodysplasia verruciformis protein 1), is an integral membrane protein located in the endoplasmic reticulum (ER) of keratinocytes and other cell types . It belongs to the transmembrane channel-like protein family and plays crucial roles in cellular zinc homeostasis, immune function, and viral resistance. TMC6 antibodies are essential research tools that enable the detection, localization, and functional analysis of this protein in various experimental settings. These antibodies help investigate the role of TMC6 in forming complexes with other proteins, its involvement in disease pathogenesis, and its regulation of cellular processes . Given the low endogenous expression of TMC6 in many cell types, sensitive and specific antibodies are particularly important for accurate detection and characterization .

What are the key characteristics of commercially available TMC6 antibodies?

Commercial TMC6 antibodies are predominantly polyclonal antibodies raised in rabbits against synthetic peptides corresponding to specific regions of human TMC6 . For instance, one antibody (ATC-006) is generated against a peptide corresponding to amino acid residues 681-695 of human TMC6 (Accession Q7Z403), targeting an intracellular, cytoplasmic domain . These antibodies are typically validated for Western blot applications, with some showing cross-reactivity with mouse TMC6 due to sequence homology . When selecting a TMC6 antibody, researchers should consider the epitope location, as this affects detection capability in different experimental approaches. Some antibodies may not detect truncated forms of the protein that result from alternative splicing or mutations associated with diseases like Epidermodysplasia Verruciformis .

What is the predicted structure and cellular localization of TMC6?

TMC6 is predicted to have 10 transmembrane domains and 2 leucine zipper motifs, characteristic of a channel or transport protein . It is predominantly localized to the endoplasmic reticulum membrane in keratinocytes and lymphocytes . In keratinocytes, TMC6 forms a complex with zinc transporter-1 (ZnT-1), facilitating zinc uptake into the ER and thereby regulating cellular zinc balance . In lymphocytes, TMC6 forms complexes with TMC8 (EVER2) and CIB1 (calcium and integrin-binding protein 1) . The protein's complex membrane topology presents challenges for antibody generation and epitope accessibility in certain applications, particularly immunohistochemistry of intact cells where transmembrane regions may be inaccessible .

How can TMC6 antibodies be used to investigate the TMC6-TMC8-CIB1 complex?

TMC6 antibodies are instrumental in studying the formation and function of the TMC6-TMC8-CIB1 heterotrimeric complex through several sophisticated approaches. Co-immunoprecipitation experiments using TMC6 antibodies can pull down TMC8 and CIB1, demonstrating their physical interaction . When combined with mass spectrometry, this approach has identified CIB1 as a protein that specifically interacts with both TMC6 and TMC8, with large numbers of CIB1 peptide spectrum matches (PSMs) detected in TMC6 and TMC8 immunoprecipitates .

For investigating the stability relationships between these proteins, researchers can employ TMC6 antibodies in Western blot analysis after manipulating expression levels through siRNA knockdown or overexpression systems. Such experiments have revealed that TMC6 and TMC8 protect CIB1 from ubiquitination and proteasomal degradation, while CIB1 reciprocally stabilizes TMC6 and TMC8 levels . To study the sequence of complex formation, TMC6 antibodies can be used in combination with CIB1 knockdown experiments, which have demonstrated that while CIB1 affects TMC6 and TMC8 protein levels, it is not required for their interaction .

What methodological approaches can overcome challenges in detecting endogenous TMC6?

Detecting endogenous TMC6 presents significant challenges due to its naturally low expression in many cell types. Research has shown that TMC6 and TMC8 proteins are not readily detectable in several mouse T cell lines and are expressed at low levels in Jurkat cells . To address this limitation, researchers should consider the following methodological approaches:

• Tissue selection: Prioritize tissues with higher endogenous expression, such as thymocytes, which show detectable TMC6 levels using Western blot, while being mindful that expression in other tissues like epidermal cells may be below detection limits .

• Protein concentration techniques: Implement immunoprecipitation prior to Western blotting to concentrate the protein of interest.

• Signal amplification systems: Utilize enhanced chemiluminescence substrates or fluorescent secondary antibodies with higher sensitivity.

• Loading controls: Include appropriate controls to verify protein loading and antibody functionality, especially when negative results are obtained.

• Overexpression systems: For functional studies, stable transduction or transfection of TMC6 in model cell lines can provide a system with detectable protein levels .

• Multiple detection antibodies: Use antibodies targeting different epitopes to improve detection probability, particularly when protein conformations may mask certain epitopes.

How do TMC6 expression patterns correlate with disease susceptibility?

TMC6 expression patterns show significant tissue-specific variations that correlate with disease susceptibility profiles. Comparative analysis of TMC6 protein levels between cell types reveals that TMC6 is expressed more than 6.6-fold higher in T cells than in keratinocytes, while TMC8 expression is very low in keratinocytes compared to lymphoid cells . This differential expression pattern helps explain the tissue-specific manifestations of diseases associated with TMC6 mutations.

In Epidermodysplasia Verruciformis (EV), mutations in TMC6 lead to extreme susceptibility to infection by cutaneous human papillomaviruses (HPV) of the beta genus . The low baseline expression of TMC6 in keratinocytes may contribute to the skin-specific manifestations of EV, as these cells have limited reserve capacity when mutations impair protein function.

Beyond EV, genetic variations in the TMC6 region have been associated with cervical cancer development , suggesting broader implications for HPV-related cancers. Additionally, limited research has explored potential connections between TMC6 and amyotrophic lateral sclerosis (ALS), with one study measuring TG6 IgG antibodies in 100 ALS patients and 81 controls, finding three seropositive individuals in each group .

For researchers investigating these correlations, TMC6 antibodies enable:

• Quantitative comparison of TMC6 expression across different tissues and cell types

• Detection of mutant forms or altered expression patterns in patient samples

• Correlation of expression levels with clinical phenotypes and disease progression

What are the optimal conditions for TMC6 antibody use in Western blotting?

Successful detection of TMC6 via Western blotting requires careful optimization of several parameters. Based on published protocols and commercial recommendations, the following technical considerations should be addressed:

• Sample preparation: For membrane proteins like TMC6, complete solubilization is critical. Lysis buffers containing 1% SDS or other strong detergents may be necessary, especially when studying protein interactions that may be disrupted by such conditions .

• Antibody dilution: Optimal dilution ratios range from 1:800 as used in published protocols to manufacturer-recommended dilutions for commercial antibodies. Titration experiments are advisable for each new experimental system.

• Detection systems: Enhanced chemiluminescence systems are typically required due to the relatively low expression of TMC6 in many tissues.

• Controls:

  • Positive controls: Rat prostate, testis, and placenta tissues have been successfully used

  • Negative controls: Tissues from TMC6 knockout mice or cells treated with TMC6 siRNA

  • Specificity controls: Pre-incubation of the antibody with the immunizing peptide should abolish specific signal

• Expected molecular weight: The TMC6 gene encodes two alternatively spliced proteins, one 805 amino acids long and another 454 amino acids in the same open reading frame . Researchers should be aware of this when interpreting Western blot results.

How can researchers validate TMC6 antibody specificity for their experimental system?

Validating antibody specificity is crucial for generating reliable data, particularly for proteins like TMC6 that may have limited commercial antibody options. A comprehensive validation strategy should include:

• Genetic validation: Compare signal between wild-type samples and those with TMC6 knockout or knockdown. Research has shown that anti-TMC6 antibodies detect distinct bands in lysates from wild-type thymocytes, while the corresponding TMC6 signals are completely absent from knockout samples .

• Peptide competition: Pre-incubate the antibody with the immunizing peptide to block specific binding. This approach has been successfully used to demonstrate specificity of anti-TMC6 antibodies in Western blot analysis of rat tissues .

• Recombinant protein controls: Express tagged versions of TMC6 (e.g., FLAG-tagged) and confirm detection with both the tag-specific antibody and the TMC6-specific antibody.

• Multiple antibodies: When possible, use multiple antibodies targeting different epitopes of TMC6 to confirm consistent results.

• Mass spectrometry validation: For immunoprecipitation experiments, confirm the identity of pulled-down proteins by mass spectrometry, as demonstrated in studies of the TMC6-TMC8-CIB1 complex .

• Cross-reactivity assessment: Test the antibody on tissues from different species to understand cross-reactivity limitations and possibilities for comparative studies.

What are the key considerations for co-immunoprecipitation experiments involving TMC6?

Co-immunoprecipitation (co-IP) is a valuable technique for studying protein-protein interactions involving TMC6, particularly its associations with TMC8 and CIB1. Based on published research, successful co-IP experiments with TMC6 should consider:

How does TMC6 regulate zinc homeostasis and what are the experimental approaches to study this function?

TMC6 plays a critical role in cellular zinc homeostasis through its interaction with zinc transporters. Located in the endoplasmic reticulum (ER) of keratinocytes, TMC6 forms a complex with zinc transporter-1 (ZnT-1), a membrane protein responsible for zinc efflux and resistance to zinc toxicity . This complex facilitates zinc uptake into the ER, thereby controlling the cellular zinc balance . Additionally, TMC6 down-regulates the activity of transcription factors induced by zinc and cytokines .

To experimentally investigate TMC6's role in zinc homeostasis, researchers can employ:

• Fluorescent zinc indicators: To measure intracellular zinc concentrations in cells with normal or disrupted TMC6 expression.

• Zinc challenge experiments: To assess cellular resistance to zinc toxicity in the presence or absence of functional TMC6.

• Reporter gene assays: To monitor the activity of zinc-responsive transcription factors when TMC6 is present, absent, or mutated.

• Co-localization studies: Using TMC6 antibodies alongside ZnT-1 antibodies to visualize their interaction at the ER membrane.

• Structure-function analysis: Through mutagenesis of TMC6 to identify domains critical for zinc transporter interaction and function.

Understanding TMC6's role in zinc homeostasis has important implications for its disease associations, as disrupted zinc balance can affect immune function, viral defense, and cellular signaling pathways.

What is the relationship between TMC6 and human papillomavirus (HPV) infections?

TMC6 plays a critical role in cellular defense against human papillomavirus (HPV) infections, particularly those of the beta genus. Mutations in the TMC6 gene are implicated in the development of Epidermodysplasia Verruciformis (EV), a rare autosomal recessive disease characterized by extreme susceptibility to infection by cutaneous HPVs . Current evidence suggests two potential mechanisms for this relationship:

• Direct viral control: TMC6 may be involved in controlling HPV gene expression and replication in epidermal keratinocytes, potentially through zinc-dependent regulatory pathways .

• Immune response regulation: TMC6 may affect innate and adaptive immune responses that control the clearance of HPV-infected keratinocytes .

Beyond EV, genetic variation in the TMC6 region has been associated with the development of cervical cancer (CxCa), a disease predominantly caused by high-risk HPV types . This suggests a broader role for TMC6 in HPV-related pathogenesis.

Experimental approaches to study this relationship include:

• Viral replication assays in keratinocytes with normal or disrupted TMC6 function

• Analysis of HPV gene expression in TMC6-deficient versus TMC6-expressing cells

• Genetic association studies in HPV-related disease cohorts

• Investigation of TMC6 expression in HPV-infected versus uninfected tissues

How do TMC6 and TMC8 cooperatively stabilize CIB1, and what experimental evidence supports this mechanism?

The stabilization of CIB1 (calcium and integrin-binding protein 1) by TMC6 and TMC8 represents a fascinating example of cooperative protein regulation. Experimental evidence from multiple approaches has elucidated this mechanism:

• Co-expression studies have demonstrated that when TMC6 and TMC8 are expressed together, CIB1 protein levels increase significantly compared to control cells . This effect is enhanced when both proteins are present compared to either alone.

• Proteasome inhibition experiments with MG-132 have shown increased CIB1 levels in control cells but minimal additional effect in TMC6/TMC8-expressing cells, indicating that TMC6 and TMC8 protect CIB1 from proteasomal degradation .

• Ubiquitination analysis has revealed that CIB1 undergoes polyubiquitination in control cells, which is elevated by proteasome inhibition. Importantly, cells expressing TMC6 and TMC8 show reduced CIB1 polyubiquitination (both in terms of the ratio relative to total protein amounts and polyubiquitin chain length) .

• Reciprocal regulation studies using CIB1 siRNA have demonstrated that CIB1 is also required for full TMC6 and TMC8 protein stability, creating a mutual stabilization circuit .

• Interaction analysis through co-immunoprecipitation following CIB1 knockdown has shown that TMC6 and TMC8 interaction does not require CIB1, suggesting they form a direct heterodimeric complex that then associates with CIB1 .

This intricate relationship explains why inactivating mutations in any of the three human genes (TMC6, TMC8, or CIB1) leads to similar clinical presentations in diseases like Epidermodysplasia Verruciformis .

What is the evidence for TMC6 antibodies in amyotrophic lateral sclerosis (ALS)?

The potential relationship between TMC6 and amyotrophic lateral sclerosis (ALS) represents an emerging area of investigation. In a case-control study conducted at an ALS tertiary center, researchers measured serum levels of various antibodies, including transglutaminase 6 (TG6) IgG antibodies, in 100 patients with ALS and 81 healthy controls . The study found that three individuals in each group were seropositive for TG6 IgG antibodies, suggesting no significant difference in the prevalence of these antibodies between ALS patients and controls .

This research was conducted in the context of exploring whether gluten-related disorders might mimic or contribute to ALS in some patients, as previous case reports had described patients initially diagnosed with ALS who were ultimately diagnosed with celiac disease and improved with a strict gluten-free diet . The study also examined other celiac disease-related antibodies and HLA antigen alleles to determine whether a neurologic presentation of a gluten-related disorder might occur in some ALS patients .

For researchers investigating this potential connection, several methodological considerations are important:

• Careful selection of patient and control cohorts with detailed clinical characterization

• Comprehensive antibody profiling beyond a single marker

• Correlation of antibody findings with clinical phenotypes and disease progression

• Functional studies to determine potential pathogenic mechanisms

While current evidence does not strongly support a role for TMC6 antibodies in ALS pathogenesis, further research with larger cohorts and more sensitive detection methods may be warranted.

How can TMC6 antibodies contribute to the study of Epidermodysplasia Verruciformis (EV)?

TMC6 antibodies are invaluable tools for investigating Epidermodysplasia Verruciformis (EV), a rare autosomal recessive disease characterized by extreme susceptibility to infection by cutaneous human papillomaviruses (HPV) of the beta genus . These antibodies enable several research approaches:

• Mutation effect analysis: By comparing TMC6 protein expression, localization, and complex formation in cells expressing wild-type versus mutant TMC6 associated with EV, researchers can elucidate how specific mutations affect protein function.

• Tissue expression profiling: Given that TMC6 expression is higher in T cells than in keratinocytes , TMC6 antibodies allow researchers to compare expression patterns between different tissues in both healthy individuals and EV patients.

• Protein-protein interaction studies: TMC6 antibodies facilitate investigation of how EV-associated mutations affect interactions with TMC8 and CIB1, as well as with zinc transporters like ZnT-1 .

• Functional rescue experiments: In cells from EV patients, reintroduction of wild-type TMC6 followed by antibody-based detection can confirm successful expression and potentially demonstrate functional rescue.

• HPV restriction mechanisms: TMC6 antibodies can help determine how TMC6 normally restricts HPV replication or gene expression in keratinocytes, and how this restriction is lost in EV.

Understanding the molecular mechanisms of EV has broader implications for comprehending host defense against viral infections and may inform therapeutic approaches not only for EV but also for other HPV-related conditions.

What are the experimental challenges in studying TMC6's role in disease states?

Investigating TMC6's role in disease states presents several experimental challenges that researchers must address through careful methodological approaches:

• Tissue-specific expression variations: TMC6 is expressed at different levels across tissues, with notably higher expression in T cells compared to keratinocytes . This variation necessitates tissue-appropriate detection methods and experimental designs tailored to the expression level in the tissue of interest.

• Complex protein interactions: TMC6 functions within a heterotrimeric complex with TMC8 and CIB1, while also interacting with zinc transporters such as ZnT-1 . Studying these interactions requires sophisticated approaches to distinguish direct from indirect effects when one component is manipulated.

• Genetic redundancy: Functional overlap between TMC family members may mask phenotypes in single-gene studies, requiring combinatorial approaches to fully elucidate function.

• Limitations of model systems: Cell line models may not fully recapitulate the physiological context of TMC6 function, particularly for studying HPV infections which have a complex life cycle dependent on keratinocyte differentiation.

• Disease-associated mutations: Mutations in TMC6 associated with conditions like EV may affect protein stability, localization, or function in subtle ways that require multiple complementary detection methods.

• Low endogenous expression: The naturally low expression of TMC6 in many cell types necessitates sensitive detection methods or controlled overexpression systems, which may introduce artifacts .

• Technical antibody limitations: Commercial antibodies may have limited specificity or sensitivity, particularly for detecting mutant forms of TMC6. Researchers should validate antibodies thoroughly with appropriate positive and negative controls .

By acknowledging and addressing these challenges through rigorous experimental design, researchers can advance our understanding of TMC6's role in various disease states and potentially identify new therapeutic targets.